Corrected quote from analyst Erin Lash in third paragraph
NEW YORK ( TheStreet) -- Heinz (HNZ) may make a run for all or part of pharmaceutical company Pfizer's (PFE) baby formula business, according to The New York Post.
The Post said Pfizer accepted first-round bids for the division over the holidays. The newspaper referred to the potential purchase as a "$9 billion transformative deal."
Morningstar analyst Erin Lash also said it would be a "transformative" deal for Heinz if the company acquires all of Pfizer's infant nutrition business, provided a deal happens at all.
"Heinz has placed an emphasis on growing its presence in emerging and developing markets, but up to now has primarily utilized organic growth or has pursued smaller bolt-on deals to broaden its distribution network," Lash said.Some of Pfizer's baby nutritional brands include Progress, Progress Gold and Promise Gold. A Pfizer spokeswoman said the company's exploration of strategic initiatives for this division is ongoing. "We're currently pursuing the activities associated with evaluating all options, including sale, spin-off or other transaction. However, no decisions have been made at this point," the spokeswoman wrote. "We expect to be in a position to announce any decision in 2012, and continue to expect to complete any transactions that may result from this decision between July 2012 and July 2013." A Heinz spokesman declined to comment. Shares of Heinz fell 17 cents to $53.07 in Tuesday's trading, while Pfizer's stock rose 10 cents to $21.92. -- Written by Alexandra Zendrian in New York.
>To contact the writer of this article, click here: Alexandra Zendrian >To submit a news tip, send an email to: firstname.lastname@example.org. >To follow the writer on Twitter, go to Alexandra Zendrian.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV